The November 2010 issue of the Journal of Commercial Biotechnology is now available. The links below will take you to the abstract for each paper:
Volume 16, Issue 4
Editorial
| For success in biotechnology, look beyond biotechnology | |
| Yali Friedman |
Commentary
| Federal bureaucrats slip on oil spill | |
| Henry I Miller |
Articles
| R&D spending and sources of funding of private US biopharmaceutical firms seeking to go public | |
| David R Williams, Richard W Pouder |
| Algae and Biodiesel: Patenting energized as green goes commercial | |
| Matthew R Preiss, Stanley P Kowalski |
| Biotechnology industry-physician interaction and OIG guidelines: Evidence from the stock market | |
| Thani Jambulingam, WaQar Ghani, Rajneesh Sharma |
| Exploratory assessment of the current EU regulatory framework for development of advanced therapies | |
| Pawanbir Singh, Laure Brévignon-Dodin, Satya P Dash |
| Patenting of microorganisms: Systems and concerns | |
| Ramkumar Balachandra Nair, Pratap Chandran Ramachandranna |
Legal and Regulatory Updates
| Legal and Regulatory Update | |
| Gerry Kamstra |
| The aftermath of Bilski | |
| Thomas C Meyers, Adam M Schoen |
| Commentary regarding decision in Bilski from a biotech perspective | |
| Thomas J Kowalski, Heidi E Lunasin, Deborah L Lu, Brian M McGuire, Frank J DeRosa |
Book Reviews
| Book Review: Biodesign: The process of innovating medical technologies | |
| Randall Tagg, Catalina Bravo |